HEXUN
和迅生命科學股份有限公司
HEXUN is a Taiwan TPEx-listed biotechnology company; its most advanced asset is HeXell-2020 (Phase 1 / Phase 2; recruiting, Coronary Artery Disease), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| HeXell-2020 | — | Phase 1 / Phase 2; recruiting | Coronary Artery Disease | Taiwan | 2026-09-29 | Trial registry |
Key events
No verified events in the past twelve months.
Related Drugnews articles
No related articles in this language.